The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity
Abstract
Background—A significant number of patients treated with anthracyclines develop cardiotoxicity (anthracycline-induced cardiotoxicity [ACT]), mainly presenting as arrhythmias (acute ACT) or congestive heart failure (chronic ACT). There are no data on pharmacogenomic predictors of ACT. Methods and Results—We genotyped participants of the German non-Hodgkin lymphoma study (NHL-B) who were followed up for the development of heart failure for a median of >3 years. Single-nucleotide polymorphisms (SNPs) were selected from 82 genes with conceivable relevance to ACT. Of 1697 patients, 55 developed acute and 54 developed chronic ACT (cumulative incidence of either form, 3.2%). We detected 5 significant associations with polymorphisms of the NAD(P)H oxidase and doxorubicin efflux transporters. Chronic ACT was associated with a variant of the NAD(P)H oxidase subunit NCF4 (rs1883112, −212A→G; symbols with right-pointing arrows, as edited?‘ odds ratio [OR], 2.5; 95% CI, 1.3 to 5.0). Acute ACT was associated with the His72Tyr polymorphism in the p22phox subunit (rs4673; OR, 2.0; 95% CI, 1.0 to 3.9) and with the variant 7508T→A (rs13058338; OR, 2.6; 95% CI, 1.3 to 5.1) of the RAC2 subunit of the same enzyme. In agreement with these results, mice deficient in NAD(P)H oxidase activity, unlike wild-type mice, were resistant to chronic doxorubicin treatment. In addition, acute ACT was associated with the Gly671Val variant of the doxorubicin efflux transporter multidrug resistance protein 1 (MRP1) (OR, 3.6; 95% CI, 1.6 to 8.4) and with the Val1188Glu-Cys1515Tyr (rs8187694-rs8187710) haplotype of the functionally similar MRP2 (OR, 2.3; 95% CI, 1.0 to 5.4). Polymorphisms in adrenergic receptors previously demonstrated to be predictive of heart failure were not associated with ACT. Conclusions—Genetic variants in doxorubicin transport and free radical metabolism may modulate the individual risk to develop ACT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Aldose reductase induction: a novel response to oxidative stress of smooth muscle cells
Spycher, S. E., Tabataba‐Vakili, S., O’Donnell, V. B., Palomba, L., & Azzi, A. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.2.9039961 · Cited by 144
RetractedHaploview: analysis and visualization of LD and haplotype maps
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bth457 · Cited by 14,525
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241205 · Cited by 1,404
Cardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy
Steinherz, L. J. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470120074036 · Cited by 989
Pollock, J. D., Williams, D. A., Gifford, M. A. C., Li, L. L., Du, X., Fisherman, J., Orkin, S. H., Doerschuk, C. M., & Dinauer, M. C. (1995) · Nature Genetics · doi:10.1038/ng0295-202 · Cited by 921
Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion
LEGHA, S. S., BENJAMIN, R. S., MACKAY, B., EWER, M., WALLACE, S., VALDIVIESO, M., RASMUSSEN, S. L., BLUMENSCHEIN, G. R., & FREIREICH, E. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-2-133 · Cited by 763
Anthracycline-Induced Cardiotoxicity
Shan, K., Lincoff, A. M., & Young, J. B. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00008 · Cited by 749
Pfreundschuh, M. (2004) · Blood · doi:10.1182/blood-2003-06-2095 · Cited by 717
Self-citation
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Doxorubicin pathways: pharmacodynamics and adverse effects
Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833ffb56 · Cited by 1,648
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., & Moens, A. L. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.03.006 · Cited by 1,414
Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111708 · Cited by 909
Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Volkova, M., & Russell, R. (2012) · Current Cardiology Reviews · doi:10.2174/157340311799960645 · Cited by 872
Smith, L. A., Cornelius, V. R., Plummer, C. J., Levitt, G., Verrill, M., Canney, P., & Jones, A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-337 · Cited by 753
Prevention of Anthracycline-Induced Cardiotoxicity
Vejpongsa, P., & Yeh, E. T. H. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.06.1167 · Cited by 671
Lipshultz, S. E., Adams, M. J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., Hudson, M. M., Kremer, L. C., Landy, D. C., Miller, T. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182a88099 · Cited by 612
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 507
Page, R. L., O’Bryant, C. L., Cheng, D., Dow, T. J., Ky, B., Stein, C. M., Spencer, A. P., Trupp, R. J., & Lindenfeld, J. (2016) · Circulation · doi:10.1161/cir.0000000000000426 · Cited by 471
Cardiac side-effects of cancer chemotherapy
Monsuez, J.-J., Charniot, J.-C., Vignat, N., & Artigou, J.-Y. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.03.003 · Cited by 467
Eschenhagen, T., Force, T., Ewer, M. S., de Keulenaer, G. W., Suter, T. M., Anker, S. D., Avkiran, M., de Azambuja, E., Balligand, J.-L., Brutsaert, D. L., et al. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq213 · Cited by 413
Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children
Visscher, H., Ross, C. J. D., Rassekh, S. R., Barhdadi, A., Dubé, M.-P., Al-Saloos, H., Sandor, G. S., Caron, H. N., van Dalen, E. C., Kremer, L. C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3467 · Cited by 401
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine
Ahmed, S., Zhou, Z., Zhou, J., & Chen, S.-Q. (2016) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.03.008 · Cited by 371
Cole, S. P. C. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.609248 · Cited by 361
Genetic Variants Associated With Cancer Therapy–Induced Cardiomyopathy
Garcia-Pavia, P., Kim, Y., Restrepo-Cordoba, M. A., Lunde, I. G., Wakimoto, H., Smith, A. M., Toepfer, C. N., Getz, K., Gorham, J., Patel, P., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037934 · Cited by 357
Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs
Cascorbi, I. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.04.009 · Cited by 355
Cappetta, D., De Angelis, A., Sapio, L., Prezioso, L., Illiano, M., Quaini, F., Rossi, F., Berrino, L., Naviglio, S., & Urbanek, K. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1521020 · Cited by 350
NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure
MURDOCH, C., ZHANG, M., CAVE, A., & SHAH, A. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.03.016 · Cited by 343
Štěrba, M., Popelová, O., Vávrová, A., Jirkovský, E., Kovaříková, P., Geršl, V., & Šimůnek, T. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4795 · Cited by 329
Chemotherapy-Induced Weakness and Fatigue in Skeletal Muscle: The Role of Oxidative Stress
Gilliam, L. A. A., & St. Clair, D. K. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.3965 · Cited by 324
Shafei, A., El-Bakly, W., Sobhy, A., Wagdy, O., Reda, A., Aboelenin, O., Marzouk, A., El Habak, K., Mostafa, R., Ali, M. A., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.09.059 · Cited by 318
Aminkeng, F., Bhavsar, A. P., Visscher, H., Rassekh, S. R., Li, Y., Lee, J. W., Brunham, L. R., Caron, H. N., van Dalen, E. C., Kremer, L. C., et al. (2015) · Nature Genetics · doi:10.1038/ng.3374 · Cited by 278
Cardiovascular toxicity caused by cancer treatment: strategies for early detection
Altena, R., Perik, P. J., van Veldhuisen, D. J., de Vries, E. G., & Gietema, J. A. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70042-7 · Cited by 257
Cancer Therapy–Induced Cardiac Toxicity in Early Breast Cancer: Addressing the Unresolved Issues
Khouri, M. G., Douglas, P. S., Mackey, J. R., Martin, M., Scott, J. M., Scherrer-Crosbie, M., & Jones, L. W. (2012) · Circulation · doi:10.1161/circulationaha.112.100560 · Cited by 255
Nox enzymes as novel targets for drug development
Lambeth, J. D., Krause, K.-H., & Clark, R. A. (2008) · Seminars in Immunopathology · doi:10.1007/s00281-008-0123-6 · Cited by 212
Clinical Potential of Spirulina as a Source of Phycocyanobilin
McCarty, M. F. (2007) · Journal of Medicinal Food · doi:10.1089/jmf.2007.621 · Cited by 199
Doxorubicin‐Induced Cardiomyopathy in Children
Mancilla, T. R., Iskra, B., & Aune, G. J. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180017 · Cited by 108
Matsa, E., Ahrens, J. H., & Wu, J. C. (2016) · Physiological Reviews · doi:10.1152/physrev.00036.2015 · Cited by 105
Zhu, S.-G., Kukreja, R. C., Das, A., Chen, Q., Lesnefsky, E. J., & Xi, L. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.01.024 · Cited by 96
Conseil, G., & Cole, S. P. C. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054213 · Cited by 28
“For example, the 2012T allele is associated with the acute anthracyclineinduced cardiotoxicity in patients with non-Hodgkin’s lymphoma (Wojnowski et al., 2005).”
Background
Metadata
- Authors
- Wojnowski, L., Kulle, B., Schirmer, M., Schlüter, G., Schmidt, A., Rosenberger, A., Vonhof, S., Bickeböller, H., Toliat, M. R., Suk, E.-K., Tzvetkov, M., Kruger, A., Seifert, S., Kloess, M., Hahn, H., Loeffler, M., Nürnberg, P., Pfreundschuh, M., Trümper, L., Brockmöller, J., & Hasenfuss, G.
- Venue
- Circulation
- Published
- 2005-12-13
- Volume
- 112
- Issue
- 24
- Pages
- 3754-3762
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2116678763
- Cited by
- 489
- References
- 46
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.